Minerva Neurosciences | NERV - Trade Creditors


Minerva Neurosciences reported $640K in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
Adma Biologics USD 20.52M 2M Mar/2026
ALKERMES USD 102.36M 5.59M Mar/2026
Alterity Therapeutics Limited AUD 1.07M 203.72K Dec/2025
AstraZeneca USD 22.51B 2.78B Mar/2026
BioCryst Pharmaceuticals USD 10.96M 4.87M Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Cipla INR 32.3B 1.95B Mar/2026
Clal Biotechnology ILS 21.05M 1.62M Dec/2021
Compugen USD 2.35M 6.77M Dec/2025
CSL USD 3.17B 290M Dec/2025
Eli Lilly USD 5.03B 350M Mar/2026
Esperion Therapeutics USD 68.41M 3.34M Mar/2026
GlaxoSmithKline GBP 14.34B 1.05B Mar/2026
Grifols EUR 987.75M 47.87M Dec/2025
Halozyme Therapeutics USD 14.1M 6.8M Mar/2026
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
J&J USD 10.46B 1.53B Mar/2026
Merck USD 3.86B 541M Mar/2026
Minerva Neurosciences USD 640K 305K Dec/2025
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.32B 134M Mar/2026
Novavax USD 16.1M 8.48M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
Roche Holding CHF 5.78B 1.27B Dec/2025
Sanofi EUR 22.71B 219M Mar/2026
Takeda JPY 491.34B 23.75B Mar/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024